Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings

Transplant Immunology

Volumn 5, Issue 3, 1997, Pages 225-232

  Zucker, Keith ^a   Rosen, Anne ^a   Tsaroucha, Alexandra ^a   De Faria, Ludmilla ^a   Roth, David ^a   Ciancio, Gaetano ^a   Esquenazi, Violet ^a   Burke, George ^a   Tzakis, Andreas ^a   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

EID: 0030670814     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(97)80042-1     Document Type: Conference Paper

References (14)

1. Sollinger HW. Mycophenolate mofetil. Kidney Int. 52:1995;S14-S17.
2. Lee W, Gu L, Miksztal A, et al. Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharm Res. 7:1990;161-166.
3. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J. 113:1969;515-524.
4. Sweeney MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res. 32:1972;1803-1809.
5. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs. 50:1995;924-941.
6. Tsina I, Kaloostian M, Lee R, Tarnowski T, Wang B. High-performance liquid chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatog B. 681:1996;347-354.
7. Zucker K, Roth D, Cirocco R, et al. Transplant associated auto-immune mechanisms in human hepatitis C virus infection. J Clin Immunol. 16:1996;60-70.
8. Chou T-C, Talalay P. Quantitative analysis of dose - effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg. 22:1984;27-55.
9. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group Transplantation. 60:1995;225-232.
10. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Therapeutic Monitoring. 17:1995;685-689.
11. Sollinger HW, Deierhoi MH, Beizer FO, Biethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation. 53:1992;428-432.
12. Fisher A, Mor E, Hytiroglou P, et al. FK506 hepatotoxicity in liver allograft recipients. Transplantation. 59:1995;1631-1632.
13. Thompson AW, Woo J, Gao GZ, Todo S, Starzl TE, Zeevi A. Effects of combined administration of FK506 and the purine biosynthesis inhibitors mizorbine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transplant Immunol. 1:1993;146-150.
14. Tanabe M, Todo S, Murase N, et al. Combined immunosuppression therapy with low dose FK506 and anti-metabolites in rat allogeneic heart transplantation. Transplantation. 58:1994;23-27.